Cargando…

PD-L1(P146R) is prognostic and a negative predictor of response to immunotherapy in gastric cancer

Cancer cells evade immune detection via programmed cell death 1/programmed cell death-ligand 1 (PD-1/PD-L1) interactions that inactivate T cells. PD-1/PD-L1 blockade has become an important therapy in the anti-cancer armamentarium. However, some patients do not benefit from PD-1/PD-L1 blockade despi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Qing, Zhou, Zhi-Wei, Lu, Jia, Luo, Hao, Wang, Shu-Nan, Peng, Yu, Deng, Meng-Sheng, Song, Guan-Bin, Wang, Jian-Min, Wei, Xi, Wang, Dong, Westover, Kenneth D., Xu, Cheng-Xiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821936/ https://www.ncbi.nlm.nih.gov/pubmed/34547468 http://dx.doi.org/10.1016/j.ymthe.2021.09.013

Ejemplares similares

PD-L1 is an independent prognostic predictor in gastric cancer of Western patients
por: Böger, Christine, et al.
Publicado: (2016)

Dysregulation of endothelial colony-forming cell function by a negative feedback loop of circulating miR-146a and -146b in cardiovascular disease patients
por: Chang, Ting-Yu, et al.
Publicado: (2017)

CD146 as an adverse prognostic factor in uterine sarcoma
por: Zhou, Yun, et al.
Publicado: (2015)

An antigen processing and presentation signature for prognostic evaluation and immunotherapy selection in advanced gastric cancer
por: Wang, Ke-wei, et al.
Publicado: (2022)

The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy
por: Jiang, Wenxiao, et al.
Publicado: (2021)

Genomic Analysis Uncovers the Prognostic and Immunogenetic Feature of Pyroptosis in Gastric Carcinoma: Indication for Immunotherapy
por: Zhou, Jie, et al.
Publicado: (2022)

PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer
por: Zhang, Yingzi, et al.
Publicado: (2022)

Prognostic and diagnostic potential of miR-146a in oesophageal squamous cell carcinoma
por: Wang, Cong, et al.
Publicado: (2016)

iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer
por: Ding, Naiqing, et al.
Publicado: (2019)

PD-L1 expression-related PI3K pathway correlates with immunotherapy efficacy in gastric cancer
por: Liu, Langbiao, et al.
Publicado: (2023)

Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy
por: Chen, Jierong, et al.
Publicado: (2022)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma
por: Hu, Zhang-Wei, et al.
Publicado: (2022)

The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors
por: Chen, Li, et al.
Publicado: (2022)

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

AFF3 is a novel prognostic biomarker and a potential target for immunotherapy in gastric cancer
por: Zeng, Yuling, et al.
Publicado: (2022)

Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis
por: Chen, Xiao-Jiang, et al.
Publicado: (2023)

Bio-functionalized dense-silica nanoparticles for MR/NIRF imaging of CD146 in gastric cancer
por: Wang, Pu, et al.
Publicado: (2015)

GADD45α sensitizes cervical cancer cells to radiotherapy via increasing cytoplasmic APE1 level
por: Li, Qing, et al.
Publicado: (2018)

Spatial predictors of immunotherapy response in triple-negative breast cancer
por: Wang, Xiao Qian, et al.
Publicado: (2023)

Consensus Molecular Subtypes Efficiently Classify Gastric Adenocarcinomas and Predict the Response to Anti-PD-1 Immunotherapy
por: Wu, Xiangyan, et al.
Publicado: (2022)

The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review
por: Chen, Ke, et al.
Publicado: (2021)

Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

Genetic variant of miR-146a rs2910164 C>G and gastric cancer susceptibility
por: Xia, Zu-Guang, et al.
Publicado: (2016)

Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
por: Yang, Tinglin, et al.
Publicado: (2023)

MicroRNA-146a Is Upregulated by and Negatively Regulates TLR2 Signaling
por: Quinn, Edel M., et al.
Publicado: (2013)

Prognostic significance of PD‐L1 expression on cell‐surface vimentin‐positive circulating tumor cells in gastric cancer patients
por: Liu, Mengyuan, et al.
Publicado: (2020)

PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor
por: Wang, Zhi-liang, et al.
Publicado: (2018)

Role of miRNA-146 in proliferation and differentiation of mouse neural stem cells
por: Xiao, Wei-Zhong, et al.
Publicado: (2015)

A systematic pan-cancer analysis identifies TRIM28 as an immunological and prognostic predictor and involved in immunotherapy resistance
por: Shang, Zhi, et al.
Publicado: (2023)

Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
por: Khan, Muhammad, et al.
Publicado: (2020)

Comprehensive Analysis of DNA Methylation and Transcriptome to Identify PD-1-Negative Prognostic Methylated Signature in Endometrial Carcinoma
por: Cao, Lu, et al.
Publicado: (2022)

Increased Expression of miR-146a in Children With Allergic Rhinitis After Allergen-Specific Immunotherapy
por: Luo, Xi, et al.
Publicado: (2016)

Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy
por: Yeong, Joe, et al.
Publicado: (2022)

Targeting Alpha‐Ketoglutarate Disruption Overcomes Immunoevasion and Improves PD‐1 Blockade Immunotherapy in Renal Cell Carcinoma
por: Li, Le, et al.
Publicado: (2023)

Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
por: Sun, Chengliang, et al.
Publicado: (2022)

BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti‐PD‐1/PD‐L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity
por: Cai, Zhiyong, et al.
Publicado: (2023)

Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis
por: Xie, Tong, et al.
Publicado: (2021)

Inhibiting the redox function of APE1 suppresses cervical cancer metastasis via disengagement of ZEB1 from E-cadherin in EMT
por: Li, Qing, et al.
Publicado: (2021)

Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: a meta-analysis
por: Liu, Yong-Xuan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_on1kddmutmv1q5cbr7m8mg33ta